MetLife Investment Advisors LLC Has $1.54 Million Stake in FibroGen Inc (FGEN)

MetLife Investment Advisors LLC trimmed its position in shares of FibroGen Inc (NASDAQ:FGEN) by 34.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 33,355 shares of the biopharmaceutical company’s stock after selling 17,701 shares during the quarter. MetLife Investment Advisors LLC’s holdings in FibroGen were worth $1,544,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Meeder Asset Management Inc. increased its position in FibroGen by 622.4% during the fourth quarter. Meeder Asset Management Inc. now owns 614 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 529 shares during the period. Intercontinental Wealth Advisors LLC acquired a new position in FibroGen during the fourth quarter worth approximately $37,000. Flinton Capital Management LLC acquired a new position in FibroGen during the fourth quarter worth approximately $44,000. Neuburgh Advisers LLC acquired a new position in FibroGen during the fourth quarter worth approximately $53,000. Finally, Bank of Montreal Can increased its position in FibroGen by 177.3% during the fourth quarter. Bank of Montreal Can now owns 1,722 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 1,101 shares during the period. Institutional investors own 66.58% of the company’s stock.

Shares of FibroGen stock traded down $0.86 during trading on Wednesday, reaching $47.07. The company’s stock had a trading volume of 310,765 shares, compared to its average volume of 673,593. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.75 and a quick ratio of 7.75. FibroGen Inc has a 12-month low of $37.27 and a 12-month high of $68.55. The company has a market cap of $4.03 billion, a PE ratio of -45.70 and a beta of 1.72.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.23 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.40. FibroGen had a negative return on equity of 16.84% and a negative net margin of 40.58%. The firm had revenue of $108.05 million for the quarter, compared to the consensus estimate of $72.15 million. During the same period in the previous year, the business earned ($0.27) earnings per share. The company’s revenue for the quarter was up 251.5% compared to the same quarter last year. On average, equities research analysts anticipate that FibroGen Inc will post -0.97 EPS for the current fiscal year.

In other FibroGen news, CEO Thomas B. Neff sold 39,636 shares of the business’s stock in a transaction on Wednesday, February 20th. The stock was sold at an average price of $57.41, for a total transaction of $2,275,502.76. Following the sale, the chief executive officer now directly owns 2,658,056 shares in the company, valued at $152,598,994.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Thomas B. Neff sold 48,180 shares of the business’s stock in a transaction on Friday, February 8th. The stock was sold at an average price of $56.47, for a total value of $2,720,724.60. Following the sale, the chief executive officer now owns 2,680,346 shares in the company, valued at $151,359,138.62. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 268,721 shares of company stock worth $14,863,268. Company insiders own 8.96% of the company’s stock.

FGEN has been the topic of a number of recent research reports. Zacks Investment Research raised FibroGen from a “hold” rating to a “buy” rating and set a $62.00 target price on the stock in a report on Friday, March 8th. Piper Jaffray Companies initiated coverage on FibroGen in a report on Friday, April 12th. They issued a “neutral” rating and a $65.00 target price on the stock. Stifel Nicolaus initiated coverage on FibroGen in a report on Monday, February 11th. They issued a “buy” rating and a $71.00 target price on the stock. BidaskClub raised FibroGen from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 10th. Finally, TheStreet raised FibroGen from a “d+” rating to a “c-” rating in a report on Friday, March 29th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $71.17.

ILLEGAL ACTIVITY WARNING: This story was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/04/24/fibrogen-inc-fgen-stake-lowered-by-metlife-investment-advisors-llc.html.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Further Reading: How is an ETF different from a mutual fund?

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.